EP3923924A4 - Composés bêta-hydroxybutyrate non racémiques et compositions enrichies avec l'énantiomère r, et leurs méthodes d'utilisation - Google Patents

Composés bêta-hydroxybutyrate non racémiques et compositions enrichies avec l'énantiomère r, et leurs méthodes d'utilisation Download PDF

Info

Publication number
EP3923924A4
EP3923924A4 EP20755289.4A EP20755289A EP3923924A4 EP 3923924 A4 EP3923924 A4 EP 3923924A4 EP 20755289 A EP20755289 A EP 20755289A EP 3923924 A4 EP3923924 A4 EP 3923924A4
Authority
EP
European Patent Office
Prior art keywords
enantiomer
methods
compositions enriched
racemic beta
hydroxybutyrate compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20755289.4A
Other languages
German (de)
English (en)
Other versions
EP3923924A1 (fr
Inventor
Gary MILLET
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axcess Global Sciences LLC
Original Assignee
Axcess Global Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/272,165 external-priority patent/US10596129B2/en
Priority claimed from US16/409,501 external-priority patent/US10596131B2/en
Priority claimed from US16/783,844 external-priority patent/US11103470B2/en
Application filed by Axcess Global Sciences LLC filed Critical Axcess Global Sciences LLC
Publication of EP3923924A1 publication Critical patent/EP3923924A1/fr
Publication of EP3923924A4 publication Critical patent/EP3923924A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
EP20755289.4A 2019-02-11 2020-02-10 Composés bêta-hydroxybutyrate non racémiques et compositions enrichies avec l'énantiomère r, et leurs méthodes d'utilisation Pending EP3923924A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16/272,165 US10596129B2 (en) 2017-11-22 2019-02-11 Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US16/409,501 US10596131B2 (en) 2017-11-22 2019-05-10 Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US16/783,844 US11103470B2 (en) 2017-11-22 2020-02-06 Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
PCT/US2020/017555 WO2020167692A1 (fr) 2019-02-11 2020-02-10 Composés bêta-hydroxybutyrate non racémiques et compositions enrichies avec l'énantiomère r, et leurs méthodes d'utilisation

Publications (2)

Publication Number Publication Date
EP3923924A1 EP3923924A1 (fr) 2021-12-22
EP3923924A4 true EP3923924A4 (fr) 2022-11-09

Family

ID=72045082

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20755289.4A Pending EP3923924A4 (fr) 2019-02-11 2020-02-10 Composés bêta-hydroxybutyrate non racémiques et compositions enrichies avec l'énantiomère r, et leurs méthodes d'utilisation

Country Status (6)

Country Link
EP (1) EP3923924A4 (fr)
JP (2) JP2022520203A (fr)
CN (1) CN114025752A (fr)
AU (1) AU2020222897A1 (fr)
CA (1) CA3129587A1 (fr)
WO (1) WO2020167692A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115153005A (zh) * 2022-07-27 2022-10-11 南京纽邦生物科技有限公司 β-羟基丁酸组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2240017T3 (da) * 2008-01-04 2019-06-17 Univ Oxford Innovation Ltd Ketonlegemer og ketonlegemsestere som blodlipid-sænkende midler
US10292952B2 (en) * 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US11173138B2 (en) * 2016-04-19 2021-11-16 Keto Patent Group, Inc. Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
US10588877B2 (en) * 2016-07-21 2020-03-17 Savind, Inc. Compositions comprising β-hydroxybutyric acid and salt, and methods of using the same
US20180057846A1 (en) * 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
EP3654963A4 (fr) * 2017-07-21 2021-04-14 Buck Institute for Research on Aging Énantiomères s de bêta-hydroxybutyrate et de butanediol et leurs procédés d'utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
AU2020222897A1 (en) 2021-09-02
JP2023166026A (ja) 2023-11-17
CA3129587A1 (fr) 2020-08-20
CN114025752A (zh) 2022-02-08
JP2022520203A (ja) 2022-03-29
EP3923924A1 (fr) 2021-12-22
WO2020167692A1 (fr) 2020-08-20

Similar Documents

Publication Publication Date Title
EP3713560A4 (fr) Composés bêta-hydroxybutyrate non racémiques et compositions enrichies en l'énantiomère r, et leurs procédés d'utilisation
EP3727360A4 (fr) Composés bêta-hydroxybutyrate non racémiques et compositions enrichies en l'énantiomère s, et leurs procédés d'utilisation
EP3755310A4 (fr) Composition pour film pour voie transmucosale et procédés de préparation et d'utilisation de celle-ci
EP3782998A4 (fr) Composé de pyrrolotriazine substitué, composition pharmaceutique et utilisation associées
EP3893917A4 (fr) Compositions d'il-15 et leurs procédés d'utilisation
EP3749403A4 (fr) Ensemble respiratoire auto-désinfectant et procédés de fabrication et d'utilisation de celui-ci
EP3740576A4 (fr) Compositions thérapeutiques et leurs procédés de préparation et d'utilisation
EP3829307A4 (fr) Compositions de bismuth-thiol et méthodes d'utilisation
EP3923925A4 (fr) Compositions de sel-acide mixtes de bêta-hydroxybutyrate racémique et procédés d'utilisation
EP3808357A4 (fr) Composition et ses applications
EP4063489A4 (fr) Composition et utilisation correspondante
EP3908293A4 (fr) Compositions de lymphocytes t activées ex vivo et leurs procédés d'utilisation
EP3978468A4 (fr) Composé et composition
EP3793563A4 (fr) Compositions comprenant des composés de bisfluoroalkyl-1,4-benzodiazépinone et méthodes d'utilisation associées
EP3677126A4 (fr) Composition d'inhibiteurs d'age, son utilisation, son procédé de préparation et sa formulation
EP3934426A4 (fr) Compositions de conservation et leurs procédés d'utilisation
EP3923918A4 (fr) Compositions de sel d'acide mixte de bêta-hydroxybutyrate et procédés d'utilisation
EP3790552A4 (fr) Compositions de combinaison comprenant des composés de bisfluoroalkyle-1,4-benzodiazépinone et leurs procédés d'utilisation
EP3762436A4 (fr) Composé macromoléculaire thermiquement stable et composition de pétrole le contenant
EP3923924A4 (fr) Composés bêta-hydroxybutyrate non racémiques et compositions enrichies avec l'énantiomère r, et leurs méthodes d'utilisation
EP4076485A4 (fr) Extraits enrichis en composés polyphénoliques et méthodes associées
EP3923916A4 (fr) Formulations de phénol injectables et leurs méthodes d'utilisation
EP3774708A4 (fr) Compositions à base d'un inhibiteur de foxm1 et procédés d'utilisation correspondantes
EP4031096A4 (fr) Composition de gel à haute teneur en huile, son procédé de préparation et son utilisation
EP4054514A4 (fr) Compositions contenant des fenchols et procédés d'utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210825

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20221011

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20221005BHEP

Ipc: A61P 3/08 20060101ALI20221005BHEP

Ipc: A23L 33/12 20160101ALI20221005BHEP

Ipc: A61K 31/19 20060101AFI20221005BHEP